People news: Savient and Lilly Oncology

Share this article:
John Johnson, SVP and president of Lilly Oncology, has resigned from the company effective January 28. He will join New Jersey-based Savient Pharmaceuticals as the company's CEO, effective January 31. Johnson's decision to resign was “driven by personal and family considerations,” according to a Lilly statement. Johnson, formerly CEO of ImClone, became SVP and president of Lilly Oncology following Lilly's acquisition of ImClone in 2008. Prior to ImClone, Johnson served as company group chairman of J&J's worldwide biopharmaceuticals unit.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.